The hurdle you must leap over to convince a federal judge to void federal regulations makes Mt. Everest look like Mt. Oread, home of my beloved Kansas Jayhawks. (I'd post pictures of both for visual interest, but I can't quite manage to get the hang of it yet).
Welcome to ECF! We need people with legal backgrounds.
No one is seeking to "void" fregs, the issue here is how we participate in the rulemaking process, which as you know is the predicate to fregs under the APA.
I need to be careful here, because I don't want to step on CASAA's toes, but broadly speaking there are several objectives:
1) Understanding the general scope of what the FDA's proposed rule allows them to do. For ex., they have made it clear that they are not extending the "accessories" language in the FSPTCA to vaping products. So if they decided to regulate Provari tee shirts without going through another rulemaking cycle, this would be one of those rare cases in which something might theoretically be done by an entity with standing (fair enough?). And as I like to remind people, the "accessories" issue is not a joke - try buying a Marlboro gym bag.
2) Understanding what specific classes of products would be covered under the proposed rule. For example, most of us believe that any "component or part" (from the statute) which is "marketed or intended for use" (not from the statute) for use with a covered "tobacco product" (from the statute) would require a separate approval process. If you're a vaper, you know what a drip tip is, and also that they're sold separately. Does that mean that the same public health studies that might normally be required for a new tobacco cigarette are going to have to be done by the company that makes Trippy Tips - these are ornate, hand made glass drip tips that retail for $20 or more?
3) Understanding what the doctrine of Substantial Equivalence actually means in this context (this is a huge can of worms, that I won't get further into, otherwise this post would get ridiculously long).
4) Understanding what legal remedies might be available at which stages of the regulatory process, and which entities (parties) might be able to invoke them (standing, and other justiciability issues).
5) Building a record that might be of use during the post-comment stages of the process - everything from OMB review to congressional review (it's not really "review" - more like a kind of "final look" under the APA), to a potential future court challenge based on either a rejected premarket application and/or a C&D letter or product siezure.
***
There are probably other goals as well, as I said - I don't want to step on CASAA's toes.
My personal objective in starting this thread was just to clear up some of the rumors and misunderstandings about the FDA's proposed rule. As I said in the OP intriduction - everyone has a natural desire to believe that everything's okay, and this will be some kind of minor dislocation at worst. Some of us a bit more willing to override this desire. Others persist in living in some kind of fantasy world.
My own unscientific guess right now is that the vast majority of the 3M US vapers have no idea what's coming, and are assuming that their access to both e-liquid and vaping equpiment will remain essentially unfettered for many years to come as a result of the kindly and beneficent FDA intervention into the market. After all, the FDA can only make vaping better, right?
Barring the intervention of a fairy godmother or some other similar mythical chimera, these happy predictions for the future seem remote.
The only thing I can say for certain is blind optimism borne of abysmal ignorance appears to be both unstoppable and inevitable.
Last edited: